Operate a price comparison platform for prescription drugs in the U.S. Provide consumers with tools to compare medication prices at local pharmacies. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The gap is $281.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 38.6× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 84% of them.
Analysts' average target sits 24% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price looks reasonable next to what the company earns.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
Over the last 4 years, sales grew only 2% a year on average — the report card’s higher growth grade leans on profit power instead.
The company’s market value is 39 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, GDRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GDRX does earn real profits — but on our report card it still sits behind its class. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.